An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia
2015; Elsevier BV; Volume: 125; Issue: 15 Linguagem: Inglês
10.1182/blood-2014-08-595934
ISSN1528-0020
AutoresJeff P. Sharman, Michael Hawkins, Kathryn S. Kolibaba, Michael Boxer, Leonard M. Klein, Meihua Wu, Jing Hu, Steve Abella, Chris Yasenchak,
Tópico(s)Immunodeficiency and Autoimmune Disorders
Referência(s)